Eiger BioPharmaceuticals, Inc. (EIGR) is a publicly traded company in the Unknown sector. Across all available filings, 19 corporate insiders have executed 104 transactions totaling $7.8M, demonstrating a bullish sentiment with $1.6M in net insider flow. The most recent transaction on Nov 2, 2023 involved a purchase of 23,398 shares valued at $7.0K.
No significant insider buying has been recorded for EIGR in the recent period.
No significant insider selling has been recorded for EIGR in the recent period.
Based on recent SEC filings, insider sentiment for EIGR is bullish with an Insider Alignment Score of 61/100 and a net flow of $1.6M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Eiger BioPharmaceuticals, Inc. (EIGR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 19 insiders are actively trading EIGR stock, having executed 104 transactions in the past 90 days. The most active insider is Ventures Fund Vi, L.p. Vivo (Executive), who has made 2 transactions totaling $3.0M.
Get notified when executives and directors at EIGR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 2, 2023 | A. Kayne Richard | Executive | Purchase | 23,398 | $0.30 | $7.0K | |
| Nov 1, 2023 | A. Kayne Richard | Executive | Purchase | 100,000 | $0.28 | $28.0K | |
| Oct 31, 2023 | Kawas Leen | Executive | Purchase | 12,345 | $0.26 | $3.2K | |
| Oct 31, 2023 | Kawas Leen | Executive | Purchase | 11,987 | $0.26 | $3.1K | |
| Oct 31, 2023 | A. Kayne Richard | Executive | Purchase | 12,345 | $0.26 | $3.2K | |
| Oct 31, 2023 | A. Kayne Richard | Executive | Purchase | 11,987 | $0.26 | $3.1K | |
| Oct 31, 2023 | A. Kayne Richard | Executive | Purchase | 130,509 | $0.24 | $31.3K | |
| Mar 17, 2023 | C. Mayer Eldon III | Executive | Sale | 1,875 | $1.07 | $2.0K | |
| Mar 17, 2023 | C. Mayer Eldon III | Executive | Sale | 2,520 | $1.07 | $2.7K | |
| Jan 23, 2023 | John Dietz Thomas | Executive | Purchase | 50,000 | $1.43 | $71.5K | |
| Dec 29, 2022 | Murray Christine | Executive | Sale | 5,000 | $1.22 | $6.1K | |
| Dec 22, 2022 | S. Glenn Jeffrey | Executive | Purchase | 100,000 | $1.28 | $128.0K | |
| Dec 22, 2022 | John Dietz Thomas | Executive | Sale | 22,500 | $1.17 | $26.3K | |
| Aug 16, 2022 | Apelian David | Executive | Sale | 5,000 | $9.81 | $49.0K | |
| Mar 14, 2022 | C. Mayer Eldon III | Executive | Sale | 1,657 | $5.60 | $9.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 44 | $4.7M | 59.2% |
Sale(S) | 13 | $3.1M | 38.5% |
Award(A) | 46 | $177.9K | 2.2% |
Exercise(M) | 1 | $8.2K | 0.1% |
Insiders at Eiger BioPharmaceuticals, Inc. are accumulating shares at an accelerated pace. With 19 insiders making 104 transactions totaling $4.7M in purchases versus $3.1M in sales, the net buying activity of $1.6M signals strong executive confidence. Ventures Fund Vi, L.p. Vivo (Executive) leads the buying activity with $3.0M in transactions across all time.